Results 11 to 20 of about 376,147 (348)

Accelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC [PDF]

Advanced Science, 2020
The gut–brain axis has attracted increasing attention in recent years, fueled by accumulating symptomatic, physiological, and pathological findings. In this study, the aggregation and toxicity of amyloid beta (Aβ), the pathogenic peptide associated with ...
Ibrahim Javed, Zhenzhen Zhang, Jozef Adamcik, Nicholas Andrikopoulos, Yuhuan Li, Daniel E. Otzen, Sijie Lin, Raffaele Mezzenga, Thomas P. Davis, Feng Ding, Pu Chun Ke   +10 more
doaj   +6 more sources

Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor [PDF]

Neurodegenerative Diseases, 2009
Alzheimer-disease-associated beta-amyloid (A beta) is produced by sequential endoproteolysis of beta-amyloid protein precursor (beta APP): the extracellular portion is shed by cleavage in the juxtamembrane region by beta-amyloid-cleaving enzyme (BACE ...
Dohi, Keiji, Fukumori, Akio, Haass, Christian, Hasegawa, Hiroshi, Hosono, Motoko, Itoh, Naohiro, Jiang, Jingwei, Kato, Akira, Katoh, Takaaki, Kikuchi, Jyunko, Kudo, Takashi, Minagawa, Kazuyuki, Mori, Kohji, Morihara, Takashi, Nakano, Yuko, Nakayama, Taisuke, Nishigaki, Atsuko, Nishimura, Masaki, Nishitomi, Kouhei, Okochi, Masayasu, Sakaguchi, Gaku, Tagami, Shinji, Takeda, Masatoshi, Takemoto, Hiroshi, Takinami, Yoshihiko, Tanaka, Toshihisa, Willem, Michael, Yanagida, Kanta   +27 more
core   +4 more sources

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Pyroglutamate‐modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra‐high‐sensitive assay is needed for detecting AβpE3‐40.
Pei‐Ning Wang, Kun‐Ju Lin, Huei‐Chun Liu, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Shieh‐Yueh Yang   +6 more
doaj   +4 more sources

Amyloid‐Beta Interaction with Mitochondria [PDF]

International Journal of Alzheimer’s Disease, 2011
Mitochondrial dysfunction is a hallmark of amyloid‐beta(Aβ)‐induced neuronal toxicity in Alzheimer′s disease (AD). The recent emphasis on the intracellular biology of Aβ and its precursor protein (AβPP) has led researchers to consider the possibility that mitochondria‐associated and/or intramitochondrial Aβ may directly cause neurotoxicity.
Pagani, Lucia, Eckert, Anne
openaire   +3 more sources

β-Amyloid Monomers Are Neuroprotective [PDF]

The Journal of Neuroscience, 2009
The 42-aa-long β-amyloid protein—Aβ1-42—is thought to play a central role in the pathogenesis of Alzheimer's disease (AD) (Walsh and Selkoe, 2007). Data from AD brain (Shankar et al., 2008), transgenic APP (amyloid precursor protein)-overexpressing mice (Lesné et al., 2006), and neuronal cultures treated with synthetic Aβ peptides (Lambert et al., 1998)
ML Giuffrida, F Caraci, B Pignataro, S Cataldo, P De Bona, V Bruno, G Molinaro, G Pappalardo, A Messina, A Palmigiano, D Garozzo, F Nicoletti, E Rizzarelli, A Copani   +13 more
openaire   +6 more sources

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance [PDF]

Frontiers in Aging Neuroscience, 2014
Accumulation of the amyloid-beta (Aβ) peptide is a central factor in Alzheimer's disease (AD) pathogenesis as supported by continuing evidence. This review concisely summarizes this evidence supporting a critical role for Aβ in AD before discussing the clearance of this peptide.
Marr, Robert A., Hafez, Daniel M.
openaire   +3 more sources

Neurotoxicity of .BETA.-amyloid.

Folia Pharmacologica Japonica, 2000
Recent observations on the neurotoxicity of beta-amyloid have been reviewed and possible roles of racemization of beta-amyloid are discussed. beta 1-40, beta 25-35 and D-Ser26 beta 25-35 (all HCl salt forms), but not commercially available beta 1-40 (TFA salt form), take the beta-structure within few hours in PBS, form fibrils, exert toxic effects on ...
I, Kaneko, T, Kubo, K, Morimoto
openaire   +3 more sources

Synapses, synaptic activity and intraneuronal Aβ in Alzheimer's disease

Frontiers in Aging Neuroscience, 2010
β-amyloid peptide accumulation plays a central role in the pathogenesis of Alzheimer’s disease. Aberrant β-amyloid buildup in the brain has been shown to be present both in the extracellular space and within neurons.
Davide Tampellini
doaj   +1 more source

Beta-amyloid imaging with florbetaben [PDF]

Clinical and Translational Imaging, 2015
Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative that was developed as a positron emission tomography (PET) tracer for routine clinical application to visualize β-amyloid plaques in the Alzheimer's disease (AD) brain. The tracer successfully completed a global multicenter phase 0-III development program and was, as a consequence, recently
Sabri, O, Seibyl, J, Rowe, C, Barthel, H
openaire   +3 more sources

Molecular basis for passive immunotherapy of Alzheimer's disease [PDF]

, 2007
Amyloid aggregates of the amyloid-{beta} (A{beta}) peptide are implicated in the pathology of Alzheimer's disease. Anti-A{beta} monoclonal antibodies (mAbs) have been shown to reduce amyloid plaques in vitro and in animal studies.
A. S. Gardberg, Bard, Br  ckner, C. Dealwis, D. G. Myszka, Davis, Dobson, E. Helmbrecht, Emsley, Frenkel, Frenkel, Gevorkian, Giudicelli, Harper, Harris, Hyman, J. Ko, Kheterpal, Kheterpal, Kodali, L. T. Dice, Lavie, Murshudov, O'nuallain, P. H. Patterson, R. L. Rich, R. Wetzel, S. Ou, Schenk, Schilling, Seubert, Solomon, Solomon, Vaguine, Walsh, Weiner, Wetzel, Williams, Wu, Zhu   +39 more
core   +3 more sources